CA2389305A1 - 28 proteines secretees humaines - Google Patents
28 proteines secretees humaines Download PDFInfo
- Publication number
- CA2389305A1 CA2389305A1 CA002389305A CA2389305A CA2389305A1 CA 2389305 A1 CA2389305 A1 CA 2389305A1 CA 002389305 A CA002389305 A CA 002389305A CA 2389305 A CA2389305 A CA 2389305A CA 2389305 A1 CA2389305 A1 CA 2389305A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- polypeptides
- human
- tissues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 460
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 244
- 241000282414 Homo sapiens Species 0.000 title abstract description 273
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
- 239000013598 vector Substances 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 398
- 229920001184 polypeptide Polymers 0.000 claims description 392
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 392
- 102000040430 polynucleotide Human genes 0.000 claims description 216
- 108091033319 polynucleotide Proteins 0.000 claims description 216
- 239000002157 polynucleotide Substances 0.000 claims description 215
- 230000014509 gene expression Effects 0.000 claims description 148
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 81
- 239000002299 complementary DNA Substances 0.000 claims description 76
- 239000000047 product Substances 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 63
- 125000003729 nucleotide group Chemical group 0.000 claims description 56
- 239000002773 nucleotide Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 47
- 230000004071 biological effect Effects 0.000 claims description 38
- 239000012472 biological sample Substances 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 25
- 238000012217 deletion Methods 0.000 claims description 20
- 230000037430 deletion Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims 8
- 238000012258 culturing Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 283
- 208000035475 disorder Diseases 0.000 abstract description 183
- 201000010099 disease Diseases 0.000 abstract description 81
- 108091026890 Coding region Proteins 0.000 abstract description 5
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 404
- 235000018102 proteins Nutrition 0.000 description 234
- 210000004027 cell Anatomy 0.000 description 219
- 206010028980 Neoplasm Diseases 0.000 description 105
- 238000011282 treatment Methods 0.000 description 87
- 238000003745 diagnosis Methods 0.000 description 63
- 239000000523 sample Substances 0.000 description 63
- 230000002062 proliferating effect Effects 0.000 description 59
- 210000001124 body fluid Anatomy 0.000 description 55
- 235000001014 amino acid Nutrition 0.000 description 54
- 230000004069 differentiation Effects 0.000 description 53
- 230000002265 prevention Effects 0.000 description 49
- 238000001514 detection method Methods 0.000 description 41
- 230000001605 fetal effect Effects 0.000 description 40
- 210000004556 brain Anatomy 0.000 description 39
- 210000001744 T-lymphocyte Anatomy 0.000 description 38
- 201000011510 cancer Diseases 0.000 description 38
- 239000003795 chemical substances by application Substances 0.000 description 35
- 210000002966 serum Anatomy 0.000 description 35
- 210000001072 colon Anatomy 0.000 description 34
- 239000003153 chemical reaction reagent Substances 0.000 description 32
- 230000035755 proliferation Effects 0.000 description 31
- 230000006907 apoptotic process Effects 0.000 description 30
- 208000012239 Developmental disease Diseases 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 29
- 239000012530 fluid Substances 0.000 description 29
- 210000002381 plasma Anatomy 0.000 description 28
- 210000001179 synovial fluid Anatomy 0.000 description 28
- 210000002700 urine Anatomy 0.000 description 28
- 206010061535 Ovarian neoplasm Diseases 0.000 description 27
- 238000009826 distribution Methods 0.000 description 27
- 230000001900 immune effect Effects 0.000 description 27
- 235000015872 dietary supplement Nutrition 0.000 description 25
- 210000000987 immune system Anatomy 0.000 description 25
- 238000009169 immunotherapy Methods 0.000 description 25
- 230000003993 interaction Effects 0.000 description 25
- 239000003446 ligand Substances 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- 239000000439 tumor marker Substances 0.000 description 25
- 208000026278 immune system disease Diseases 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 24
- 210000002751 lymph Anatomy 0.000 description 24
- 206010033128 Ovarian cancer Diseases 0.000 description 23
- 239000002585 base Substances 0.000 description 23
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 22
- 230000003412 degenerative effect Effects 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 230000001413 cellular effect Effects 0.000 description 21
- 230000001537 neural effect Effects 0.000 description 21
- 206010039073 rheumatoid arthritis Diseases 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 21
- 230000030833 cell death Effects 0.000 description 20
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 20
- 208000002320 spinal muscular atrophy Diseases 0.000 description 20
- 230000028993 immune response Effects 0.000 description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 18
- 230000033228 biological regulation Effects 0.000 description 18
- 210000000349 chromosome Anatomy 0.000 description 18
- 210000001672 ovary Anatomy 0.000 description 18
- 210000002826 placenta Anatomy 0.000 description 18
- 210000001550 testis Anatomy 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 210000003169 central nervous system Anatomy 0.000 description 17
- 208000014674 injury Diseases 0.000 description 17
- 210000000440 neutrophil Anatomy 0.000 description 17
- 208000016192 Demyelinating disease Diseases 0.000 description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 230000006399 behavior Effects 0.000 description 16
- 210000004443 dendritic cell Anatomy 0.000 description 16
- 230000003463 hyperproliferative effect Effects 0.000 description 16
- 230000008929 regeneration Effects 0.000 description 16
- 238000011069 regeneration method Methods 0.000 description 16
- 210000002536 stromal cell Anatomy 0.000 description 16
- 230000008569 process Effects 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 14
- 208000015122 neurodegenerative disease Diseases 0.000 description 14
- 210000002460 smooth muscle Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 206010003246 arthritis Diseases 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 13
- 208000032839 leukemia Diseases 0.000 description 13
- 208000029462 Immunodeficiency disease Diseases 0.000 description 12
- 230000001594 aberrant effect Effects 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 210000002458 fetal heart Anatomy 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 208000000509 infertility Diseases 0.000 description 12
- 230000036512 infertility Effects 0.000 description 12
- 231100000535 infertility Toxicity 0.000 description 12
- 208000030507 AIDS Diseases 0.000 description 11
- 206010009900 Colitis ulcerative Diseases 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 11
- 208000035473 Communicable disease Diseases 0.000 description 11
- 206010012289 Dementia Diseases 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 108700026244 Open Reading Frames Proteins 0.000 description 11
- 206010039710 Scleroderma Diseases 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 201000006704 Ulcerative Colitis Diseases 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000003394 haemopoietic effect Effects 0.000 description 11
- 230000005965 immune activity Effects 0.000 description 11
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 208000002874 Acne Vulgaris Diseases 0.000 description 10
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 10
- 206010012305 Demyelination Diseases 0.000 description 10
- 208000009329 Graft vs Host Disease Diseases 0.000 description 10
- 206010018691 Granuloma Diseases 0.000 description 10
- 102000000589 Interleukin-1 Human genes 0.000 description 10
- 108010002352 Interleukin-1 Proteins 0.000 description 10
- 206010029379 Neutrophilia Diseases 0.000 description 10
- 201000004681 Psoriasis Diseases 0.000 description 10
- 206010040047 Sepsis Diseases 0.000 description 10
- 208000021386 Sjogren Syndrome Diseases 0.000 description 10
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 10
- 206010000496 acne Diseases 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000030741 antigen processing and presentation Effects 0.000 description 10
- 230000001363 autoimmune Effects 0.000 description 10
- 230000005784 autoimmunity Effects 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 10
- 230000024245 cell differentiation Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000008482 dysregulation Effects 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 210000005153 frontal cortex Anatomy 0.000 description 10
- 210000000777 hematopoietic system Anatomy 0.000 description 10
- 208000007475 hemolytic anemia Diseases 0.000 description 10
- 230000009610 hypersensitivity Effects 0.000 description 10
- 230000008105 immune reaction Effects 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 208000004235 neutropenia Diseases 0.000 description 10
- 230000007261 regionalization Effects 0.000 description 10
- 230000024833 regulation of cytokine production Effects 0.000 description 10
- 201000000980 schizophrenia Diseases 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 10
- 208000037816 tissue injury Diseases 0.000 description 10
- 230000017423 tissue regeneration Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000019399 Colonic disease Diseases 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000036737 immune function Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 210000000496 pancreas Anatomy 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 210000003606 umbilical vein Anatomy 0.000 description 9
- 206010002329 Aneurysm Diseases 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000001850 reproductive effect Effects 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 7
- 206010010356 Congenital anomaly Diseases 0.000 description 7
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 7
- 208000023105 Huntington disease Diseases 0.000 description 7
- 206010026749 Mania Diseases 0.000 description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 206010033864 Paranoia Diseases 0.000 description 7
- 208000027099 Paranoid disease Diseases 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 230000003511 endothelial effect Effects 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 210000004013 groin Anatomy 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 210000002752 melanocyte Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000009826 neoplastic cell growth Effects 0.000 description 7
- 208000019906 panic disease Diseases 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- 206010003805 Autism Diseases 0.000 description 6
- 208000020706 Autistic disease Diseases 0.000 description 6
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 201000009906 Meningitis Diseases 0.000 description 6
- 208000028017 Psychotic disease Diseases 0.000 description 6
- 206010058571 Spinal cord infarction Diseases 0.000 description 6
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 6
- 208000000323 Tourette Syndrome Diseases 0.000 description 6
- 208000016620 Tourette disease Diseases 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000019771 cognition Effects 0.000 description 6
- 206010014599 encephalitis Diseases 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 210000004700 fetal blood Anatomy 0.000 description 6
- 230000013632 homeostatic process Effects 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 230000004968 inflammatory condition Effects 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000013016 learning Effects 0.000 description 6
- 201000003723 learning disability Diseases 0.000 description 6
- 230000036244 malformation Effects 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 230000004031 neuronal differentiation Effects 0.000 description 6
- 230000006576 neuronal survival Effects 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 210000002741 palatine tonsil Anatomy 0.000 description 6
- 230000008447 perception Effects 0.000 description 6
- 208000027232 peripheral nervous system disease Diseases 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000020431 spinal cord injury Diseases 0.000 description 6
- 210000000225 synapse Anatomy 0.000 description 6
- 230000005062 synaptic transmission Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 210000004381 amniotic fluid Anatomy 0.000 description 5
- 210000001638 cerebellum Anatomy 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 201000010260 leiomyoma Diseases 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 201000004595 synovitis Diseases 0.000 description 5
- 208000003200 Adenoma Diseases 0.000 description 4
- 206010001985 Amoebic colitis Diseases 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 206010033963 Parathyroid tumour Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 206010042971 T-cell lymphoma Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 210000004727 amygdala Anatomy 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 208000002458 carcinoid tumor Diseases 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 230000008951 colonic inflammation Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 208000023965 endometrium neoplasm Diseases 0.000 description 4
- 206010057271 eosinophilic colitis Diseases 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 210000001652 frontal lobe Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000002873 global sequence alignment Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 201000002529 islet cell tumor Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 201000005296 lung carcinoma Diseases 0.000 description 4
- 230000003349 osteoarthritic effect Effects 0.000 description 4
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 210000005267 prostate cell Anatomy 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- -1 allelic variants Proteins 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000005220 cytoplasmic tail Anatomy 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 102000047217 human NR4A3 Human genes 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 101100335897 Caenorhabditis elegans gly-9 gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 102100020873 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 241000283986 Lepus Species 0.000 description 2
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000004996 female reproductive system Anatomy 0.000 description 2
- 102000006482 fibulin Human genes 0.000 description 2
- 108010044392 fibulin Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 208000016055 micropapillary serous carcinoma Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 208000005963 oophoritis Diseases 0.000 description 2
- 208000025661 ovarian cyst Diseases 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 2
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- 206010050702 Crush syndrome Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 208000007522 Fused Kidney Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 230000010556 Heparin Binding Activity Effects 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000294754 Macroptilium atropurpureum Species 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100348047 Mus musculus Ncam2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 description 1
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 101100109292 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-13 gene Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101150006573 PAN1 gene Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010068033 Renal fusion anomaly Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000025044 Thymus disease Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000017504 atelosteogenesis type II Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 208000012106 cystic neoplasm Diseases 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004987 germinal b lymphocyte Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 108010003871 heme receptor Proteins 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000003669 immune deficiency disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000005830 kidney abnormality Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000015625 metaphyseal chondrodysplasia Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000013363 skeletal muscle disease Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Nouvelles protéines sécrétées humaines et acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. La présente invention concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison destinés à produire lesdites protéines humaines sécrétées. Elle concerne en outre des méthodes diagnostiques et thérapeutiques utiles pour diagnostiquer et traiter des maladies, des troubles et/ou des états pathologiques associés à ces nouvelles protéines.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16358199P | 1999-11-05 | 1999-11-05 | |
| US60/163,581 | 1999-11-05 | ||
| US21513300P | 2000-06-30 | 2000-06-30 | |
| US60/215,133 | 2000-06-30 | ||
| PCT/US2000/030045 WO2001034626A1 (fr) | 1999-11-05 | 2000-11-01 | 28 proteines secretees humaines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2389305A1 true CA2389305A1 (fr) | 2001-05-17 |
Family
ID=26859771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002389305A Abandoned CA2389305A1 (fr) | 1999-11-05 | 2000-11-01 | 28 proteines secretees humaines |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1237901A4 (fr) |
| JP (1) | JP2003520030A (fr) |
| AU (1) | AU1449001A (fr) |
| CA (1) | CA2389305A1 (fr) |
| WO (1) | WO2001034626A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1155117A4 (fr) * | 1998-12-30 | 2003-05-14 | Millennium Pharm Inc | Proteines secretees et acides nucleiques codant ces proteines |
| DE60128008T2 (de) | 2000-12-05 | 2008-01-10 | Wisconsin Alumni Research Foundation, Madison | Rezeptor für ein toxin aus bacillus anthracis |
| US20030148920A1 (en) * | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
| EP1365801A4 (fr) * | 2001-03-08 | 2004-10-13 | Nuvelo Inc | Methodes et materiels se rapportant a des polypeptides et a des polynucleotides apparentes a la fibuline |
| WO2005000099A2 (fr) * | 2003-06-09 | 2005-01-06 | Genzyme Corporation | Domaines de facteurs sanguins (bfd) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000058473A2 (fr) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx» |
| AU2001261024A1 (en) * | 2000-04-12 | 2001-10-30 | Delta Biotechnology Limited | Albumin fusion proteins |
-
2000
- 2000-11-01 AU AU14490/01A patent/AU1449001A/en not_active Abandoned
- 2000-11-01 CA CA002389305A patent/CA2389305A1/fr not_active Abandoned
- 2000-11-01 EP EP00976756A patent/EP1237901A4/fr not_active Withdrawn
- 2000-11-01 JP JP2001537337A patent/JP2003520030A/ja not_active Withdrawn
- 2000-11-01 WO PCT/US2000/030045 patent/WO2001034626A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001034626A1 (fr) | 2001-05-17 |
| EP1237901A4 (fr) | 2005-01-12 |
| EP1237901A1 (fr) | 2002-09-11 |
| JP2003520030A (ja) | 2003-07-02 |
| AU1449001A (en) | 2001-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050239099A1 (en) | 27 human secreted proteins | |
| EP1218408A1 (fr) | 32 proteines humaines secretees | |
| US6936691B2 (en) | Secreted protein HCE3C63 | |
| CA2389722A1 (fr) | 15 proteines secretees humaines | |
| EP1224285A2 (fr) | 27 proteines humaines secretees | |
| WO2001036432A2 (fr) | 18 proteines secretees humaines | |
| CA2390438A1 (fr) | Nouvelles proteines 19 secretees par l'homme | |
| CA2395838A1 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2384264A1 (fr) | Polynucleotides recepteurs de proteine tyrosine kinase (ptk), polypeptides et anticorps ptk | |
| US20030036646A1 (en) | Uncoupling protein polynucleotides, polypeptides, and antibodies | |
| US20050010042A1 (en) | 26 human secreted proteins | |
| CA2398275A1 (fr) | Polynucleotides, polypeptides et anticorps humains | |
| CA2385884A1 (fr) | 26 proteines secretees humaines | |
| US20070172830A1 (en) | Antibodies to hhpen62 polypeptide | |
| CA2389305A1 (fr) | 28 proteines secretees humaines | |
| CA2390421A1 (fr) | 24 proteines humaines secretees | |
| EP1220865A1 (fr) | 43 proteines secretees humaines | |
| CA2397502A1 (fr) | Polynucleotides de serine/threonine-phosphatases, polypeptides et anticorps | |
| CA2384584A1 (fr) | 38 proteines secretees humaines | |
| WO2001034627A1 (fr) | 28 proteines humaines secretees | |
| WO2001032676A1 (fr) | 25 proteines secretes par l'homme | |
| CA2387754A1 (fr) | 10 proteines humaines secretees | |
| US20060099575A9 (en) | 67 human secreted proteins | |
| WO2001034767A2 (fr) | 22 proteines humaines secretees | |
| CA2389326A1 (fr) | 35 proteines humaines secretees |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |